Intellia is a leading genome editing company, focused on the development of potentially curative therapeutics utilizing the CRISPR/Cas9 system. The Company’s mission is to develop gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Recent News
Upcoming Events
Monday, November 7, 2016 11:30 a.m. MT
Credit Suisse Healthcare Conference
Wednesday, November 16, 2016
Jefferies 2016 London Healthcare Conference
Stock Information
NASDAQ  |  NTLA (Common Stock)
$13.78 + 1.32
Stock chart for: NTLA.O.  Currently trading at $13.78 with a 52 week high of $30.40 and a 52 week low of $11.86.
10/21/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
IR Contacts

John Graziano
Trout Group, LLC

Chad Rubin
Trout Group, LLC